GLP-1 Peptide Synthesis CDMO Market Accelerates as CDMOs Invest in Green and Scalable Technologies

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "GLP-1 Peptide Synthesis CDMO Market"-, By Synthesis Technology (Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), Group-Assisted Purification Peptide Synthesis (GAP-PS), Hybrid Technology, Recombinant DNA Technology), By Service Type (Analytical and Process Development, Large-Scale Production, Custom Peptide Synthesis, Peptide Modification, Purification Technology, Formulation Development, Regulatory Support, Packaging and Labeling, Pre-Formulation and Registration Batches), By Scale of Operation (Clinical-Scale Manufacturing, Commercial-Scale Manufacturing, Pilot-Scale Manufacturing), By End-User(Pharmaceutical Companies, Biotechnology Companies, Research Institutions, and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034."

Global GLP-1 Peptide Synthesis CDMO Market Size is predicted to grow at a 12.7 % CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3105

A GLP-1 peptide synthesis Contract Development and Manufacturing Organization (CDMO) is a specialized service provider that offers end-to-end support for the development, synthesis, and GMP-compliant production of Glucagon-Like Peptide-1 (GLP-1) analogues. These synthetic peptides emulate the activity of the natural GLP-1 hormone, playing a critical role in the management of type 2 diabetes and obesity by promoting insulin secretion and regulating blood glucose levels. CDMOs provide pharmaceutical and biotechnology companies with technical expertise in solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), ensuring the efficient production of high-purity peptides. These processes often include chemical modifications-such as fatty acid conjugation-to extend peptide half-life and require stringent control over peptide folding, bioactivity, stability, and regulatory compliance.

The increasing complexity of peptide manufacturing, coupled with significant capital requirements and the need for specialized technical capabilities, is leading many pharmaceutical companies to outsource GLP-1 peptide production to CDMOs. Recent advancements in SPPS and LPPS methodologies have greatly improved manufacturing efficiency, scalability, and yield. Furthermore, the integration of artificial intelligence and machine learning is reshaping the peptide development landscape. For example, companies like ImmunoPrecise Antibodies are utilizing AI-driven design approaches to engineer GLP-1 analogues with enhanced receptor activation profiles compared to existing treatments such as semaglutide.

The anticipated expiration of patents for leading GLP-1 therapeutics-including semaglutide-is further stimulating demand for generic and biosimilar peptide APIs. This trend is prompting CDMOs to expand their manufacturing capabilities and employ advanced purification technologies such as high-performance liquid chromatography (HPLC) and mass spectrometry. Additionally, the growing number of small and mid-sized biotechnology firms without in-house synthesis infrastructure is contributing to the demand for CDMOs offering flexible, small-scale manufacturing solutions suitable for preclinical studies and clinical trials.

List of Prominent Players in the GLP-1 Peptide Synthesis CDMO Market:
• Bachem Holding AG
• CordenPharma
• PolyPeptide Group
• AmbioPharm
• CPC Scientific
• CSBio
• Creative Peptides
• Lonza
• Aurisco Pharmaceutical
• Hybio Pharmaceuticals
• Chinese Peptide Company
• Neuland Laboratories
• Divis Laboratories
• Supriya Lifescience
• Allsino Pharmaceutical Co. Ltd

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The escalating global incidence of type 2 diabetes and obesity is significantly increasing the demand for GLP-1 receptor agonists, such as semaglutide and tirzepatide, which are widely prescribed for glycemic control and weight management. Given the technical complexity and high cost associated with peptide synthesis, pharmaceutical companies are increasingly turning to Contract Development and Manufacturing Organizations (CDMOs) to optimize production costs and access specialized expertise. These CDMOs provide comprehensive services ranging from early-stage process development to large-scale commercial manufacturing, thereby serving as strategic partners to both global pharmaceutical corporations and emerging biotech firms.

Technological advancements in solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and automation are further contributing to improved production scalability, efficiency, and consistency. Additionally, the expiration of patents for blockbuster GLP-1 therapeutics, such as semaglutide, is stimulating the market for generics and biosimilars. In response, CDMOs are expanding their manufacturing capabilities to produce high-quality, bioequivalent peptide-based drugs that meet growing global demand.

Challenges:
Despite favorable market conditions, large-scale peptide synthesis remains capital-intensive and technically demanding. The high cost of raw materials, complex synthetic procedures, and the use of specialized reagents contribute significantly to overall production costs. Moreover, GLP-1 analogues are structurally complex and frequently yield low purification efficiencies, which further complicates the manufacturing process and reduces cost-effectiveness. These factors underscore the need for continued investment in process innovation, purification optimization, and advanced synthesis technologies to enhance yield and operational efficiency.

Regional Trends:
North America is expected to retain a dominant share of the GLP-1 peptide synthesis CDMO market throughout the forecast period, supported by its well-established pharmaceutical manufacturing infrastructure, robust regulatory framework, and substantial clinical demand for GLP-1-based therapies. The United States, in particular, is a major global hub for drug development and commercialization and is one of the largest consumers of GLP-1 receptor agonists. The presence of highly experienced CDMOs with GMP-certified facilities and strong compliance with FDA regulations further enhances the region's strategic position in peptide contract manufacturing.

In contrast, the Asia-Pacific region is projected to witness the fastest growth, driven by cost-effective manufacturing capabilities, expanding healthcare systems, and rising regional demand for diabetes and obesity treatments. Countries including China, India, and Japan are making significant investments in biopharmaceutical infrastructure, particularly in advanced peptide production technologies. These developments are positioning Asia-Pacific as an increasingly important center for global CDMO services in peptide synthesis.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/3105

Recent Developments:
• In Aug 2024, PolyPeptide, has teamed up to work on creating a GLP-1 agonist using a more environmentally friendly production process. The initiative will operate for the next 12 months after receiving a 1 million SEK prize from Sweden's innovation agency, Vinnova. GLP-1 receptor agonist medicines are in high demand worldwide for treating diabetes and obesity. The production of peptides typically involves a high process mass intensity and the extensive use of dangerous solvents like N, N-dimethylformamide (DMF).
• In Sept2023, CordenPharma was pleased to announce the opening of expanded commercial peptide production capacity at CordenPharma Colorado, the world's biggest solid-phase peptide synthesis (SPPS) manufacturing plant, with recently renovated facilities. Beginning capital investments in early 2023, CordenPharma has successfully finished many facilities upgrades and modernizations that have improved the productivity and efficiency of SPPS peptide production. This has given the company more capacity to serve both present and future clients across a growing base of pharmaceutical innovators.
Segmentation of GLP-1 Peptide Synthesis CDMO Market.

Global GLP-1 Peptide Synthesis CDMO Market - By Synthesis Technology
• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Group-Assisted Purification Peptide Synthesis (GAP-PS)
• Hybrid Technology
• Recombinant DNA Technology
Global GLP-1 Peptide Synthesis CDMO Market - By Service Type
• Analytical and Process Development
• Large-Scale Production
• Custom Peptide Synthesis
• Peptide Modification
• Purification Technology
• Formulation Development
• Regulatory Support
• Packaging and Labeling
• Pre-Formulation and Registration Batches
Global GLP-1 Peptide Synthesis CDMO Market - By Scale of Operation
• Clinical-Scale Manufacturing
• Commercial-Scale Manufacturing
• Pilot-Scale Manufacturing
Global GLP-1 Peptide Synthesis CDMO Market - By End-User
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutions
Global GLP-1 Peptide Synthesis CDMO Market - By Region
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/glp-1-peptide-synthesis-cdmo-market/3105

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.